On Thursday, April 7, the Centers for Medicare and Medicaid (CMS) formalized its plan to cover the anti-amyloid drug Aduhelm only for patients enrolled in clinical trials. However, in response to ...
NEW YORK, March 17, 2026 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional ...
The Alzheimer's Drug Discovery Foundation (ADDF) today announced that its Co-Founder and Chief Science Officer (CSO), Dr. Howard Fillit, is retiring, transitioning to an emeritus role, marking the ...
The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, ...
Findings point to continued momentum toward combination therapies that target the full pathobiology of the disease NEW YORK, May 14, 2026 /PRNewswire/ -- Today, Biogen announced topline results from ...
San Francisco, CA (November 30, 2022) – The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal ...
(MENAFN- PR Newswire) Amyloid-targeting drugs make up one part of the biology of aging approach and are the first step in developing multiple drugs to treat Alzheimer's disease NEW YORK, May 3, 2023 ...
Please provide your email address to receive an email when new articles are posted on . The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate ...
The Frontier Awards are the most prestigious ones and are regarded as the "Oscars" of the Duty Free industry. The award was given to the ADDF during the 19th Tax Free World Exhibition, held in Cannes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results